Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists

Prostate Cancer and Prostatic Diseases volume 12, pages 100–103 (2009)Cite this article

Abstract

We present a case report of a patient with prostate cancer who failed to demonstrate consistent testosterone suppression to castration levels and incomplete suppression of serum prostate-specific antigen, although treated with gonadotropin releasing hormone agonists for 48 months. Serum dehydroepiandrosterone, dehydroepiandrosterone sulphate, as well as the androgen metabolite, androsterone glucuronide, were elevated compared to the other patients. The present data suggest that those prostate cancer patients who have even marginally elevated adrenal androgens may especially benefit from combined androgen blockade.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Huggins C, Hodges CV . Studies on prostatic cancer. I. The effect of castration on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–296.

    CAS  Google Scholar 

  2. Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005; 26: 361–379.

    Article  CAS  PubMed  Google Scholar 

  3. Crawford ED, DeAntoni EP . Current status of combined androgen blockade: optimal therapy for advanced prostate cancer. J Clin Endocrinol Metab 1995; 80: 1062–1066.

    CAS  PubMed  Google Scholar 

  4. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–424.

    Article  CAS  PubMed  Google Scholar 

  5. Labrie F, Cusan L, Seguin C, Bélanger A, Pelletier G, Reeves J et al. Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man. Int J Fertil 1980; 25: 157–170.

    CAS  PubMed  Google Scholar 

  6. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet 2000; 355: 1491–1496.

  7. Schlegel PN, Kuzma P, Frick J, Farkas A, Gomahr A, Spitz I et al. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology 2001; 58: 578–582.

    Article  CAS  PubMed  Google Scholar 

  8. Chertin B, Spitz I M, Lindenberg T, Algur N, Zer T, Kuzma P et al. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol 2000; 163: 838–844.

    Article  CAS  PubMed  Google Scholar 

  9. Belanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40–80-year-old men. J Clin Endocrinol Metab 1994; 79: 1086–1090.

    CAS  PubMed  Google Scholar 

  10. Labrie F, Belanger A, Belanger P, Bérubé R, Martel C, Cusan L et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006; 99: 182–188.

    Article  CAS  PubMed  Google Scholar 

  11. Oefelein MG, Cornum R . Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164: 726–729.

    Article  CAS  PubMed  Google Scholar 

  12. Ogan K, Berger M, Ball R . Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma. J Urol 1998; 160: 497–498.

    Article  CAS  PubMed  Google Scholar 

  13. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007; 67: 5033–5041.

    Article  CAS  PubMed  Google Scholar 

  14. Heracek J, Richard H, Martin H, Luboslav S, Jana S, Jitka K et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 2007; 72: 375–380.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Institute of Hormone Research, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel

    I M Spitz & H Hartman

  2. Department of Urology, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel

    B Chertin, A Fridmans & A Farkas

  3. The Oncology and Molecular Endocrinology Research Center, Laval University Medical Center, Quebec City, Quebec, Canada

    A Belanger & F Labrie

Authors
  1. I M Spitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Chertin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Fridmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Farkas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Belanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Hartman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Labrie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Chertin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spitz, I., Chertin, B., Fridmans, A. et al. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. Prostate Cancer Prostatic Dis 12, 100–103 (2009). https://doi.org/10.1038/pcan.2008.15

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2008.15

Keywords

Search

Advanced search

Quick links